Unique Pharmaceuticals Labs recalled 9,936 bottles of Cetirizine Hydrochloride Tablets on September 12, 2025. The tablets were imprinted with the wrong ID, posing a potential health risk. Consumers should stop using the product immediately and seek guidance from healthcare providers.
Tablet/Capsules Imprinted with Wrong ID
Consumers and healthcare providers should stop using this product immediately. Contact JB Chemicals and Pharmaceuticals Ltd or your healthcare provider for guidance. Notification method: Letter
The recall involves Cetirizine Hydrochloride Tablets USP 10 mg, sold in 100-tablet bottles. The lot number is PY925014A and the expiration date is January 31, 2028.
The tablets have an incorrect imprint, which can lead to confusion and improper use. This recall falls under Class III, indicating a potential risk but not likely to cause serious health consequences.
No specific injuries or incidents have been reported in connection with this recall. The risk remains high due to the potential for consumer confusion.
Consumers should stop using the recalled tablets immediately. Contact JB Chemicals and Pharmaceuticals Ltd or your healthcare provider for further guidance.
For more information, consumers can visit the FDA website at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0032-2026.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.